Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash from Financing Activities (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Cash from Financing Activities for 14 consecutive years, with -$49308.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities changed N/A year-over-year to -$49308.0, compared with a TTM value of $1.8 million through Sep 2025, down 76.21%, and an annual FY2024 reading of $7.4 million, up 214.18% over the prior year.
  • Cash from Financing Activities was -$49308.0 for Q3 2025 at BioRestorative Therapies, down from $888138.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $21.1 million in Q4 2021 and bottomed at -$126316.0 in Q4 2024.
  • Average Cash from Financing Activities over 4 years is $3.3 million, with a median of $569069.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities crashed 252.05% in 2024, then skyrocketed 7015.35% in 2025.
  • Year by year, Cash from Financing Activities stood at $21.1 million in 2021, then plummeted by 99.61% to $83073.0 in 2023, then plummeted by 252.05% to -$126316.0 in 2024, then skyrocketed by 60.96% to -$49308.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for BRTX at -$49308.0 in Q3 2025, $888138.0 in Q2 2025, and $1.1 million in Q1 2025.